Mereo BioPharma Group plc American Depositary Shares
Symbol: MREO (NASDAQ)
2.06
0.00 0.000
Company Description:
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Key Stats
- Today's Open: $2.06
- Today's High: $2.1
- Today's Low: $2.015
- Today's Volume: 1.41M
- Yesterday Close: $2.06
- Yesterday High: $2.08
- Yesterday Low: $1.91
- Yesterday Volume: 1.90M
- Last Min Volume: 6
- Last Min High: $2.06
- Last Min Low: $2.06
- Last Min VWAP: $2.06
Company Profile
- Name: Mereo BioPharma Group plc American Depositary Shares
- Website: https://www.mereobiopharma.com
- Listed Date: 2018-04-24
- Location: LONDON,
- Market Status: Active
- CIK Number: 0001719714
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $327.74M
- Round Lot: 100
- Outstanding Shares: 159.10M
- Asset Type: ADRC
RECENT FILINGS FOR MREO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-10 | 8-K | View |
| 2025-06-11 | SCHEDULE 13G | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-05-14 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-04-08 | ARS | View |
| 2025-04-08 | DEF 14A | View |
| 2025-04-04 | SCHEDULE 13G | View |
| 2025-03-26 | 10-K | View |
| 2025-03-26 | 8-K | View |
| 2025-02-12 | SCHEDULE 13G/A | View |
| 2025-02-06 | 4 | View |
| 2025-02-06 | 4 | View |
Latest News on MREO